regimen, with survival of 16 versus 27% respectively, hazard ratio 1.33 (95% CI 1.01-1.77; P ¼ 0.05). 8 When interpreted in the context of our meta-analysis results, the trial results questions the role of fludarabine, cytarabine and priming G-CSF in patients with high-risk AML.
Supplementary Information accompanies the paper on the Leukemia website (http://www.nature.com/leu) Downregulated expression of genes mapping on chromosome 9 in chronic myeloid leukemia cases bearing genomic deletions on der(9) Genomic deletions flanking the breakpoint on der(9)t(9;22) occur in 10-18% of patients with chronic myeloid leukemia (CML). These microdeletions have a variable extension and involve sequences on chromosomes 9 and/or 22, located proximally to the ABL and distally to the BCR gene. 1 The deletions on der(9) are associated with a poor prognosis of interferon-a (IFN-a) therapy, whereas controversial data about their influence on the response to imatinib are available. 2, 3 The molecular mechanisms responsible for this unfavorable prognosis are still unclear. The most probable hypothesis is that microdeletions could be associated with the loss of tumor suppressor genes or genes implicated in cell-cycle regulation, resulting in a proliferative advantage of the leukemic clone. 4 This phenomenon may act by a gene dosage effect known as haploinsufficiency: mutation or loss of a single allele may be sufficient to elicit a cellular phenotype that leads to tumorigenesis without the inactivation of the second allele.
The aim of our study was therefore to assess whether the sequences loss on der(9) in CML patients was associated with a gene product decrease. To date, an expression study of genes mapping within the deleted regions on der(9) has never been performed. We have reported earlier a detailed molecular cytogenetic characterization of 60 (18%) out of 334 CML patients, using panels of bacterial artificial chromosome clones mapping next to the t(9;22) breakpoint. 5 We showed that the extent of the genomic deletion on der(9) ranged from a few hundred kilobases to many megabases, causing the loss of several genes with a known function.
To provide more accurate information about the significance of the deletion status of these genes with respect to their functional biological meaning, we performed an expression analysis of 28 genes by quantitative real-time PCR in 30 CML patients (see Supplementary Information for full description of Materials and methods). Expression data analysis, performed by the relative expression software tool, 6 revealed a lower level of all the 28 examined target gene transcripts in the group of deleted patients as compared with CML cases without deletions (Supplementary Table) . However, the difference was statistically significant for six genes: protein kinase PKNbeta (PKN3, P ¼ 0.003), SH3-domain GRB2-like endophilin B2 (SH3GLB2, P ¼ 0.0018), protein phosphatase 2A regulatory subunit B Table) . All the six downregulated genes are located on chromosome 9 sequences, centromeric to the ABL gene ( Figure 1b ) and are implicated in crucial cellular pathways. It can be noted that the downregulated genes USP20 and TOR1B were lost in 67% of the 30 CML patients bearing der(9) deletions identified in our study. Low levels of TOR1B transcripts could confer to the cell a greater vulnerability to oxidative stress, as this protein is involved in conformational modeling of proteins and protection from stress. USP20 possesses a deubiquitinating activity and controls the cellular lifetime together with localization of many critical proteins. The loss of PPP2R4, ASB6, SH3GLB2 and PKN3 was detected in 60, 57, 43 and 33% of cases with deletions, respectively. Noteworthily, the PPP2R4 gene is one of the regulatory subunits of the phosphatase 2A (PP2A) protein, a serine/threonine phosphatase, which acts as a tumor suppressor in CML by antagonizing BCR-ABL. The inactivation of PP2A has been reported earlier to be associated with disease progression in CML, as its activity in blast crisis patient cells is markedly inhibited.
7 ASB6 contains a C-terminal SOCS box motif, typical of negative regulators of the cytokine receptors. SH3GLB2 is involved in the activation of the apoptotic cell death mechanism and in mediating the generation of signaling complexes. PKN3 is one of the target protein kinases for the small GTPase Rho and can be regulated by various signal transduction pathways that mediate cell growth and transformation. The subset of genes mapping on chromosome 22 did not reveal any statistically significant downregulation (Supplementary Table) . Earlier papers took into consideration the potential role, in the pathogenesis of CML with der(9) deletion, of the tumor suppressor gene SWI/SNFrelated, matrix-associated actin (SMARCB1) gene, which is implicated in leukemogenesis through the remodeling of a local chromatin structure. 1 In this study, we could not confirm a significant downregulation of the SMARCB1 gene, excluding its involvement in the poor prognosis of this subset of patients. It can be noted that all six downregulated genes were located inside a region starting at 1 Mb up to 2 Mb centromeric to ABL (Figure 1b) . This observation could clarify earlier results showing a worse outcome for CML patients with large deletions. 8 The downregulation did not affect all these six genes at the same time, but at least one of them was significantly downregulated in 19 out of 21 patients (90%) bearing chromosome 9 sequences loss of 41 Mb. All the nine patients with a deletion of p1 Mb did not Letters to the Editor show any significant downregulation of the genes mapping on chromosome 9 deleted sequences (case nos. 22-30) ( Table 1) . Among the 21 patients bearing chromosome 9 sequences deletion on der(9) 41 Mb, 7 (33%) did not respond to IFN-a therapy. Among six (29%) patients treated with imatinib as a firstline treatment, five (83%) obtained a complete cytogenetic response (CCyR). Among five patients started imatinib therapy in the late chronic phase (CP) after IFN-a treatment failure, three (60%) did not achieve any kind of cytogenetic response, whereas the remaining two (case no. 6 and 8) obtained CCyR. A total of nine (30%) patients showed the loss of chromosome 9 genomic sequences of p1 Mb. Among them, three (33%) were treated with IFN-a and none of them obtained response and three (33%) patients started imatinib as a first-line therapy and achieved CCyR. Two patients were treated with imatinib after failure to respond to IFN-a: the first one was in blast crisis and did not achieve response to treatment (case no. 22), the second one was in late CP and obtained CCyR (case no. 25) ( Table 1 ). In the overall survival analysis, there was no statistically significant difference between the patients with chromosome 9 sequences deletions of p1 Mb and those with 41 Mb (data not shown). Our patient series was too heterogeneous in terms of treatment to be able to draw definite conclusions regarding the important topic of the impact of der(9) deletions on the response to imatinib therapy. However, we must point out that (i) none of the CML patients with deletions of chromosome 9 sequences 41 Mb, representing half of the total deleted cases, responded to IFN-a therapy; (ii) the majority of CML patients with der(9) deletions 41 Mb treated with imatinib as a first-line treatment achieved CyCR and (iii) the majority of CML patients with der(9) deletions 41 Mb treated with imatinib in late CP did not achieve cytogenetic response. Therefore, it seems that the presence of deletions may exert a prognostic impact with regard to response to imatinib treatment, especially when it is administered in late CP. In fact, it is possible that the insufficient gene dosage effect observed in these cases may easily be neutralized in the early rather than late CP of CML, probably because a lasting haploinsufficiency may be able to trigger several cellular pathways accountable for the absence of response to imatinib therapy.
In conclusion, we have shown, for the first time, a downregulated expression of genes located on the der(9) chromosome in CML patients bearing genomic microdeletions. These findings support the haploinsufficiency hypothesis, suggesting that in these cases one allele could be insufficient to ensure an adequate gene expression dosage even though the occurrence of other mechanisms, such as epigenetic gene silencing, cannot be excluded. Overall, differences of the gene expression levels were detected in 70% of our series of CML cases with der(9) deletions; however, the biological meaning and clinical implications of this gene downregulation remain to be investigated. Microarrays for gene expression profiling offers important research tools for novel classification of leukemia's and lymphomas, which may have implications for prognosis and treatment. 1, 2 In the field of hematologic malignancies, several papers have demonstrated that the use of microarrays indeed may provide novel information at diagnosis. Using Affymetrix oligonucleotide microarrays, distinct expression profiles have been described for the different cytogenetically defined subgroups of acute lymphoblastic leukemia (ALL).
2 Subsequently, also prognostic and disease progression markers have been proposed, ultimately leading to the prospect of patient-tailored therapy. 2 However, so far no clear prognostic profiles have been defined. In addition, microarray-based comparisons of paired diagnosis-relapse samples [3] [4] [5] from patients with B-precursor ALL have been performed, but so far, not many studies have used this approach. Also, some studies focussed on the identification of glucocorticoid-response genes in children with ALL, comparing diagnosisFday 8 gene expression profiles. 6, 7 Treatment of pediatric ALL is increasingly based on the concept of tailoring the intensity of treatment to the risk of treatment failure or success.
Clinical studies have shown that it is possible to stratify patients according to the levels of minimal residual disease (MRD) after induction therapy and early during further treatment, as it has been demonstrated that the MRD level is the best predictive level for disease outcome. In previous studies we reported that slow responding subclones represent the clones causative for leukemic relapse in oligoclonal disease. 8, 9 On the basis of these results, we now hypothesize that the gene expression profile of the slowresponding subclones still present after the first weeks of chemotherapy might be different from the profiles of all leukemic cells at diagnosis, and are more predictive for outcome as subclones are being selected during induction therapy.
To study these differences in the expression profiles of leukemic cells, we selected 26 genes (5 genes from Staal et al. 3 and 21 top-ranked genes from Beesley et al. 4 ) that showed differential expression in diagnosis and relapse, originating from the above-mentioned studies that compared gene expression levels between diagnosis and relapse in B-precursor ALL.
Gene sequences (mRNA and genomic DNA) were obtained from public databases NCBI (http://www.ncbi.nlm.nih.gov) and BLAT (http://genome.ucsc.edu/cgi-bin/hgBlat). Primer design was performed using Primer Express 2.0 and Oligo6. Finally, for 23 genes, adequate primers were designed, showing specific amplification (Table 1) .
Paired diagnosis-day15-relapse samples from three relapsed B-precursor ALL patients were analyzed. On the basis of the markers expressed on the tumor cells (CD34, CD19, and CD10) cryopreserved mononuclear cells obtained from Ficoll density centrifugation before cryopreservation, were purified using an MOFlo High Performance Cell Sorter. Total RNA was extracted from these cell subsets following the TRIZOL protocol, subsequently followed by cDNA synthesis. RNA integrity was assessed using an Agilent 2100 BioAnalyser (Santa Clara, CA, USA). The expression levels of 23 genes were determined in a SYBR Green based real-time PCR assay.
All Ct values were normalized to b-glucuronidase (GUS) expression. We compared the expression levels in diagnosis and
